RU2008143550A - Комбинации терапевтических средств, предназначенные для лечения рака - Google Patents
Комбинации терапевтических средств, предназначенные для лечения рака Download PDFInfo
- Publication number
- RU2008143550A RU2008143550A RU2008143550/15A RU2008143550A RU2008143550A RU 2008143550 A RU2008143550 A RU 2008143550A RU 2008143550/15 A RU2008143550/15 A RU 2008143550/15A RU 2008143550 A RU2008143550 A RU 2008143550A RU 2008143550 A RU2008143550 A RU 2008143550A
- Authority
- RU
- Russia
- Prior art keywords
- rapamycin
- derivatives
- inhibitor
- combination according
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
1. Комбинация, содержащая !(а) соединение - ингибитор mTOR, выбранное из группы, включающей рапамицин, 40-O-алкильные производные рапамицина, 40-O-гидроксиалкильные производные рапамицина, 40-O-алкоксиалкильные производные рапамицина, 32-дезоксопроизводные рапамицина и 32-гидроксипроизводные рапамицина, 16-O-замещенные производные рапамицина, производные рапамицина, ацилированные на атоме кислорода в положении 40, производные рапамицина, замещенные в положении 40 гетероциклилом и 40-O-фосфосодержащие производные рапамицина, и ! (б) одно или несколько фармацевтически действующих веществ, выбранных из группы, включающей стероид, алкилирующий агент; антиметаболит; вещество, связывающее микротрубочки; ингибитор фосфатидинилинозитол-3-киназы; соединение платины; ингибитор синтеза полиаминов; ингибитор семейства тирозинкиназ SRC; ингибитор топоизомеразы и их смесь. ! 2. Комбинация по п.1, в которой одно или несколько фармацевтически действующих веществ выбраны из группы, включающей преднизон тиотепа; N1,N12-диэтилспермин·4HCl, 8-фенил-2-(морфолин-4-ил)хромен-4-он, 3-(4-хлорфенил)-1-(1,1-диметилэтил)-1Н-пиразоло[3,4-d]пиримидин-4-амин (9CI), цитарабин; кладрибин; виндесина сульфат; винорелбин; карбоплатин; идарубицина гидрохлорид, имитоксантрона гидрохлорид и их смесь. ! 3. Комбинация по п.1 или 2, где соединение - ингибитор mTOR выбран из группы, включающей 40-O-(2-гидрокси)-этилрапамицин, CCI779, АВТ578 и АР23573. ! 4. Комбинация по п.3, где ингибитор mTOR представляет собой 40-O-(2-гидрокси)-этилрапамицин. ! 5. Комбинация по п.1 или 2, где ингибитор mTOR представляет собой соединение формулы !! в которой R1 обозначает СН3 или С3-С6алкинил, ! R2 обозначает Н или -СН2-СН2-ОН и ! Х обозна
Claims (16)
1. Комбинация, содержащая
(а) соединение - ингибитор mTOR, выбранное из группы, включающей рапамицин, 40-O-алкильные производные рапамицина, 40-O-гидроксиалкильные производные рапамицина, 40-O-алкоксиалкильные производные рапамицина, 32-дезоксопроизводные рапамицина и 32-гидроксипроизводные рапамицина, 16-O-замещенные производные рапамицина, производные рапамицина, ацилированные на атоме кислорода в положении 40, производные рапамицина, замещенные в положении 40 гетероциклилом и 40-O-фосфосодержащие производные рапамицина, и
(б) одно или несколько фармацевтически действующих веществ, выбранных из группы, включающей стероид, алкилирующий агент; антиметаболит; вещество, связывающее микротрубочки; ингибитор фосфатидинилинозитол-3-киназы; соединение платины; ингибитор синтеза полиаминов; ингибитор семейства тирозинкиназ SRC; ингибитор топоизомеразы и их смесь.
2. Комбинация по п.1, в которой одно или несколько фармацевтически действующих веществ выбраны из группы, включающей преднизон тиотепа; N1,N12-диэтилспермин·4HCl, 8-фенил-2-(морфолин-4-ил)хромен-4-он, 3-(4-хлорфенил)-1-(1,1-диметилэтил)-1Н-пиразоло[3,4-d]пиримидин-4-амин (9CI), цитарабин; кладрибин; виндесина сульфат; винорелбин; карбоплатин; идарубицина гидрохлорид, имитоксантрона гидрохлорид и их смесь.
3. Комбинация по п.1 или 2, где соединение - ингибитор mTOR выбран из группы, включающей 40-O-(2-гидрокси)-этилрапамицин, CCI779, АВТ578 и АР23573.
4. Комбинация по п.3, где ингибитор mTOR представляет собой 40-O-(2-гидрокси)-этилрапамицин.
6. Фармацевтическая композиция, содержащая комбинацию по любому из пп.1-5.
7. Товарная упаковка, содержащая комбинацию по любому из пп.1-5.
8. Товарная упаковка по п.7, в которой стандартная доза представляет собой фиксированную комбинацию.
9. Применение комбинации по любому из пп.1-5 для приготовления лекарственного средства, предназначенного для предупреждения или лечения пролиферативных заболеваний или заболеваний, ассоциированных с постоянным ангиогенезом у млекопитающего или инициируемых им.
10. Применение по п.9, где пролиферативное заболевание выбрано из рака яичника, карциномы легкого и меланомы.
11. Применение фармацевтической композиции по п.6 для приготовления лекарственного средства, предназначенного для предупреждения или лечения пролиферативных заболеваний или заболеваний, ассоциированных с постоянным ангиогенезом у млекопитающего или инициируемых им.
12. Применение по п.11, где пролиферативное заболевание выбрано из рака яичника, карциномы легкого и меланомы.
13. Способ предупреждения или лечения пролиферативного заболевания, заключающийся в том, что применяют комбинацию по любому из пп.1-5.
14. Способ по п.13, где пролиферативное заболевание выбрано из рака яичника, карциномы легкого и меланомы.
15. Способ предупреждения или лечения пролиферативного заболевания, заключающийся в том, что применяют фармацевтическую композицию по п.6.
16. Способ по п.15, где пролиферативное заболевание выбрано из рака яичника, карциномы легкого и меланомы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78940006P | 2006-04-05 | 2006-04-05 | |
US60/789,400 | 2006-04-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011149721/02A Division RU2011149721A (ru) | 2006-04-05 | 2011-12-07 | Комбинации терапевтических средств, предназначенные для лечения рака |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008143550A true RU2008143550A (ru) | 2010-05-27 |
RU2447891C2 RU2447891C2 (ru) | 2012-04-20 |
Family
ID=38625696
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008143550/15A RU2447891C2 (ru) | 2006-04-05 | 2007-04-05 | Комбинации терапевтических средств, предназначенные для лечения рака |
RU2011149721/02A RU2011149721A (ru) | 2006-04-05 | 2011-12-07 | Комбинации терапевтических средств, предназначенные для лечения рака |
RU2014110184/15A RU2014110184A (ru) | 2006-04-05 | 2014-03-17 | Комбинации терапевтических средств, предназначенные для лечения рака |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011149721/02A RU2011149721A (ru) | 2006-04-05 | 2011-12-07 | Комбинации терапевтических средств, предназначенные для лечения рака |
RU2014110184/15A RU2014110184A (ru) | 2006-04-05 | 2014-03-17 | Комбинации терапевтических средств, предназначенные для лечения рака |
Country Status (11)
Country | Link |
---|---|
US (2) | US20090098137A1 (ru) |
EP (2) | EP2004163B1 (ru) |
JP (3) | JP2009532503A (ru) |
KR (2) | KR20080108517A (ru) |
CN (2) | CN101415409B (ru) |
AU (1) | AU2007240548A1 (ru) |
BR (1) | BRPI0709750A2 (ru) |
CA (1) | CA2645633A1 (ru) |
MX (1) | MX2008012715A (ru) |
RU (3) | RU2447891C2 (ru) |
WO (1) | WO2007124252A2 (ru) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010001141A (es) | 2007-07-31 | 2010-03-01 | Limerick Biopharma Inc | Analogos fosforiladosde pirona y metodos. |
US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
CA2719134C (en) * | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
AU2009279661A1 (en) * | 2008-08-05 | 2010-02-11 | Emory University | Use of mTOR inhibitors to enhance T cell immune responses |
US20100261776A1 (en) * | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US9095592B2 (en) * | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US20110280886A1 (en) * | 2008-11-12 | 2011-11-17 | University Hospital Basel | Treating cancer by modulating mnk |
CA2748931A1 (en) * | 2009-01-14 | 2010-07-22 | Health Research Inc. | Methods and compositions containing mtor inhibitors for enhancing immune responses |
CA2789847A1 (en) * | 2010-02-15 | 2011-08-18 | Synovo Gmbh | Kinase modulators for the treatment of cancer |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
US9856210B2 (en) * | 2010-09-02 | 2018-01-02 | Kyoto University | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
JP2013545757A (ja) * | 2010-11-17 | 2013-12-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 癌の治療方法 |
US8673914B2 (en) | 2011-03-28 | 2014-03-18 | St. John's University | Use of phosphodiesterase inhibitors for treating multidrug resistance |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
RU2607594C2 (ru) * | 2011-12-16 | 2017-01-10 | Пфайзер Инк. | Комбинация инотузумаба озогамицина и торизела для лечения рака |
CN104797267A (zh) | 2012-06-26 | 2015-07-22 | 德玛医药 | 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法 |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
CN105407889B (zh) | 2013-03-15 | 2018-06-01 | G1治疗公司 | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 |
CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
JP6800750B2 (ja) * | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
WO2015026934A1 (en) * | 2013-08-20 | 2015-02-26 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
BR112016009200A8 (pt) * | 2013-10-25 | 2020-03-24 | Pharmacyclics Llc | uso de um inibidor de btk e um inibidor imune do ponto de verificação |
WO2015134399A1 (en) * | 2014-03-03 | 2015-09-11 | Eisai R&D Management Co., Ltd. | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
MD20160118A2 (ru) | 2014-05-15 | 2017-04-30 | Iteos Therapeutics | Пирролидин-2,5-дионовые производные, фармацевтические композиции и способы применения в качестве ингибиторов IDO1 |
GB201409488D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
RU2599577C2 (ru) * | 2015-01-21 | 2016-10-10 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук | Амиды n-(2-аминопурин-6-ил)-6-аминокапроновой кислоты, обладающие противоопухолевой активностью, и способ их получения |
WO2016144678A1 (en) * | 2015-03-12 | 2016-09-15 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic azole pesticides |
EP3271354A1 (en) | 2015-03-17 | 2018-01-24 | Pfizer Inc | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
CA2929848A1 (en) * | 2015-05-14 | 2016-11-14 | Pfizer Inc. | Combination therapies comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-pd1/anti-pd-l1 antibody |
AU2016287508B2 (en) * | 2015-06-29 | 2021-10-14 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy |
KR20230165356A (ko) | 2015-06-29 | 2023-12-05 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
JP2018522028A (ja) * | 2015-07-31 | 2018-08-09 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の組み合わせ及びそれらの使用 |
US10544095B2 (en) | 2015-08-10 | 2020-01-28 | Pfizer Inc. | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
US20180311356A1 (en) * | 2015-10-19 | 2018-11-01 | The Children's Medical Center Corporation | Method to inhibit endothelial-to-mesenchymal transition |
JP6968080B2 (ja) * | 2016-03-02 | 2021-11-17 | メディヴィル・アクチエボラーグ | ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法 |
CN110035759A (zh) | 2016-12-05 | 2019-07-19 | G1治疗公司 | 化疗方案期间免疫反应的保持 |
KR102129067B1 (ko) * | 2016-12-29 | 2020-07-08 | 한국과학기술연구원 | 신규 엑소좀 계열 항암제 |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
WO2023028430A2 (en) * | 2021-08-25 | 2023-03-02 | Molecular Technologies Laboratories Llc | Growth hormone antagonist and anti-cancer composition combination therapy |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (ru) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
CA2264908C (en) | 1996-09-06 | 2006-04-25 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
UA71587C2 (ru) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
KR100716272B1 (ko) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
DE60028740T2 (de) | 1999-03-30 | 2007-05-24 | Novartis Ag | Phthalazinderivate zur behandlung von entzündlichen erkrankungen |
DE60010098T2 (de) | 1999-08-24 | 2005-03-31 | Ariad Gene Therapeutics, Inc., Cambridge | 28-epirapaloge |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
PT3351246T (pt) * | 2001-02-19 | 2019-06-07 | Novartis Pharma Ag | Derivado de rapamicina para o tratamento de um tumor sólido associado a angiogenese desregulada |
SG152906A1 (en) * | 2001-04-06 | 2009-06-29 | Wyeth Corp | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
SG153647A1 (en) * | 2001-06-01 | 2009-07-29 | Wyeth Corp | Antineoplastic combinations |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
IL162595A0 (en) * | 2002-01-14 | 2005-11-20 | Novartis Ag | Combinations comprising epothilones and antimetabolites |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
KR20120084333A (ko) * | 2004-02-23 | 2012-07-27 | 노파르티스 포르슝스티프퉁 쯔바이크니덜라쑹 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 | Mtor 억제제와 세포독성제의 복합 치료에 대한 바이오마커로서의 p53 야생형 |
EP1809276A4 (en) * | 2004-09-30 | 2009-06-17 | Ariad Pharma Inc | PROCESSING PROCESS |
DK1827437T3 (da) * | 2004-12-15 | 2012-02-13 | Sigma Tau Ind Farmaceuti | Kombinationer af terapeutiske midler til cancerbehandling |
CN103110948A (zh) * | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
CA2629245C (en) * | 2005-11-21 | 2016-07-12 | Novartis Ag | Neuroendocrine tumor treatment |
JP5372737B2 (ja) * | 2006-03-13 | 2013-12-18 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | Egfrキナーゼ阻害剤およびegfrキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療 |
-
2007
- 2007-04-05 CN CN2007800122755A patent/CN101415409B/zh not_active Expired - Fee Related
- 2007-04-05 EP EP07781370.7A patent/EP2004163B1/en not_active Revoked
- 2007-04-05 EP EP13152306.0A patent/EP2591775A1/en not_active Withdrawn
- 2007-04-05 BR BRPI0709750-6A patent/BRPI0709750A2/pt not_active IP Right Cessation
- 2007-04-05 CN CN201210139390.1A patent/CN102671196B/zh not_active Expired - Fee Related
- 2007-04-05 RU RU2008143550/15A patent/RU2447891C2/ru not_active IP Right Cessation
- 2007-04-05 US US12/294,141 patent/US20090098137A1/en not_active Abandoned
- 2007-04-05 KR KR1020087024231A patent/KR20080108517A/ko active IP Right Grant
- 2007-04-05 MX MX2008012715A patent/MX2008012715A/es not_active Application Discontinuation
- 2007-04-05 WO PCT/US2007/066010 patent/WO2007124252A2/en active Application Filing
- 2007-04-05 JP JP2009504469A patent/JP2009532503A/ja active Pending
- 2007-04-05 KR KR1020147001487A patent/KR20140019032A/ko active IP Right Grant
- 2007-04-05 CA CA002645633A patent/CA2645633A1/en not_active Abandoned
- 2007-04-05 AU AU2007240548A patent/AU2007240548A1/en not_active Abandoned
-
2011
- 2011-08-26 US US13/218,752 patent/US20120129881A1/en not_active Abandoned
- 2011-12-07 RU RU2011149721/02A patent/RU2011149721A/ru unknown
-
2013
- 2013-12-06 JP JP2013253326A patent/JP2014058561A/ja active Pending
- 2013-12-06 JP JP2013253325A patent/JP2014058560A/ja active Pending
-
2014
- 2014-03-17 RU RU2014110184/15A patent/RU2014110184A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2014110184A (ru) | 2015-09-27 |
WO2007124252A3 (en) | 2008-05-22 |
CN102671196B (zh) | 2014-12-03 |
CN101415409B (zh) | 2012-12-05 |
EP2591775A1 (en) | 2013-05-15 |
CA2645633A1 (en) | 2007-11-01 |
WO2007124252A2 (en) | 2007-11-01 |
US20090098137A1 (en) | 2009-04-16 |
JP2014058561A (ja) | 2014-04-03 |
MX2008012715A (es) | 2008-10-14 |
KR20140019032A (ko) | 2014-02-13 |
KR20080108517A (ko) | 2008-12-15 |
EP2004163A2 (en) | 2008-12-24 |
CN102671196A (zh) | 2012-09-19 |
CN101415409A (zh) | 2009-04-22 |
JP2014058560A (ja) | 2014-04-03 |
BRPI0709750A2 (pt) | 2011-07-26 |
EP2004163B1 (en) | 2014-09-17 |
AU2007240548A1 (en) | 2007-11-01 |
RU2011149721A (ru) | 2013-06-20 |
US20120129881A1 (en) | 2012-05-24 |
RU2447891C2 (ru) | 2012-04-20 |
JP2009532503A (ja) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008143550A (ru) | Комбинации терапевтических средств, предназначенные для лечения рака | |
US20240091177A1 (en) | Methods for treating cancer | |
RU2407532C9 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
TWI667021B (zh) | 二氫檞皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途 | |
KR102634247B1 (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
JP4694127B2 (ja) | Zd6474とタキサンとを含む組み合わせ療法 | |
BR112020019134A2 (pt) | produtos de combinação que compreendem inibidor de bcl-2 e mab anti-cd20, ou inibidor de bcl-2, mab anti-cd20 e bendamustina, ou inibidor de bcl-2 e chop e usos terapêuticos dos mesmos | |
MX2014009303A (es) | Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer. | |
JP2015524847A (ja) | 小細胞肺がんを治療するためのベンゾジアゼピン | |
Taha et al. | Synthesis, anti-leishmanial and molecular docking study of bis-indole derivatives | |
KR101100786B1 (ko) | 암에 대한 방사선 치료 증진용 조성물 | |
JP5289310B2 (ja) | 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤 | |
ES2324051T3 (es) | Extractos terapeuticos obtenidos a partir de calomeria amarnthoides y sus usos. | |
EA021951B1 (ru) | Противораковая комбинация | |
WO2021048417A1 (en) | Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma | |
EP3854397A1 (en) | Cancer combination therapy using quinoline carboxamide derivative | |
EP2263751B1 (en) | Isoxazole compound for the treatment of gastrointestinal cancers | |
Zhang et al. | Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway | |
TWI355935B (en) | Combination of a taxane and a cyclin-dependent kin | |
JP2007535521A (ja) | 抗腫瘍剤耐性を処置するのに有用なインドール誘導体 | |
US20220409582A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
US20230167100A1 (en) | Quinoline compounds and compositions for inhibiting ezh2 | |
ES2535452B1 (es) | Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas | |
RU2005132175A (ru) | Комбинированное лечение опухолей, включающее неморубицин и лучевую терапию | |
WO2021048419A1 (en) | Combination therapies comprising trametinib for the treatment of cholangiocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150406 |